Redpoint Investment Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
Other funds holding BIIB
Redpoint Investment Management's BIIB Position: Q3 2022 in Review
Redpoint Investment Management reduced its Biogen (BIIB) stake by 1.1% in Q3 2022, selling an estimated $9.98K and leaving 4,187 shares worth $1.12M. The position accounts for 0.16% of the portfolio, ranked #152.
Redpoint Investment Management first reported a position in BIIB in Q4 2017 and has held it in 20 quarters since. The position peaked at $7.11M in Q3 2018. 986 funds tracked by Wall St. Rank hold BIIB as of Q3 2022.
- Redpoint Investment Management held 4,187 shares of Biogen worth $1.12M as of Q3 2022.
- Redpoint Investment Management sold 47 Biogen shares in Q3 2022, an estimated $9.98K.
- Biogen made up 0.16% of Redpoint Investment Management's portfolio in Q3 2022, its #152 holding.
- Redpoint Investment Management first reported a position in Biogen in Q4 2017 and has held it in 20 quarters since.
- Redpoint Investment Management's Biogen position peaked at $7.11M in Q3 2018.
- 986 funds tracked by Wall St. Rank held Biogen as of Q3 2022.
Based on Redpoint Investment Management's 13F filing for Q3 2022, filed 14 Oct 2022.